Regulatory Inspection
USFDA Completes Pre-License Inspection at Dr. Reddy’s Biologics Facility; Issues Form 483 with Seven Observations
NSE
drreddy
BSE
500124
Dr. Reddy’s Laboratories Limited announced that the US Food & Drug Administration (USFDA) has completed a Pre-License Inspection (PLI) at its biologics manufacturing facility in Bachupally, Hyderabad. The inspection concluded with the issuance of a Form 483 containing seven observations, which the company said it will address within the stipulated timeline.
PRICE-SENSITIVE TRIGGER
Event: Completion of USFDA Pre-License Inspection (PLI) at biologics manufacturing facility.
Type: Regulatory Inspection (Form 483 Issued)
Impact: Neutral
Immediate Effect: The USFDA completed the inspection conducted between June 16 and June 25, 2026, and issued a Form 483 with seven observations. Dr. Reddy’s stated that it will respond to the observations within the prescribed regulatory timeline.
Key Metrics:
- Inspection Period: June 16 – June 25, 2026
- Facility: Biologics Manufacturing Facility, Bachupally, Hyderabad
- Regulatory Agency: United States Food & Drug Administration (USFDA)
- Form Issued: Form 483
- Number of Observations: 7
Highlight:
- The USFDA concluded the Pre-License Inspection with seven Form 483 observations, which Dr. Reddy’s intends to address within the stipulated timeframe.
What Happened ?
The United States Food & Drug Administration (USFDA) completed a Pre-License Inspection (PLI) at Dr. Reddy’s biologics manufacturing facility located in Bachupally, Hyderabad.
The inspection was conducted between June 16 and June 25, 2026. At the conclusion of the inspection, the company received a Form 483 containing seven observations.
Dr. Reddy’s stated that it will address all observations within the stipulated regulatory timeline. The company also noted that the inspection is a continuation of earlier inspections and disclosures made to stock exchanges on October 12, 2023, and September 13, 2025.
Key Details
Inspection Summary:
- USFDA completed a Pre-License Inspection (PLI) at the Bachupally biologics manufacturing facility.
- Inspection was conducted from June 16 to June 25, 2026.
- The agency issued a Form 483 upon completion of the inspection.
- The Form 483 contains seven observations.
- Dr. Reddy’s has committed to responding within the stipulated timeline.
- The inspection forms part of the ongoing regulatory review process for the biologics facility.
- The company referenced its previous disclosures related to inspections made in October 2023 and September 2025.
Note:
- A Form 483 represents the USFDA investigator’s inspectional observations and does not constitute a final regulatory determination. Companies are typically provided an opportunity to submit corrective actions and responses.
Risk Analysis
Summary:
- The issuance of a Form 483 is a routine regulatory outcome following many USFDA inspections. The key consideration is the company’s ability to satisfactorily address the observations within the prescribed timeframe.
Key Risks:
- Timely resolution of all seven observations will be required.
- Additional regulatory review may depend on the adequacy of corrective actions.
- Delays in addressing observations could impact regulatory timelines.
- Any future enforcement action would depend on the USFDA’s assessment of the company’s response.
Worst Case:
- If the USFDA determines that the company’s corrective actions are inadequate, it could delay regulatory approvals or require additional compliance measures.
Risk Level: Medium
Company Commentary
- The USFDA completed the Pre-License Inspection at the Bachupally biologics manufacturing facility.
- The inspection concluded with the issuance of a Form 483 containing seven observations.
- Dr. Reddy’s stated that it will address the observations within the stipulated timeline.
- The company noted that this inspection is a continuation of previous regulatory inspections disclosed in 2023 and 2025.
Official Exchange Filing: Dr. Reddy’s Laboratories Limited
